Lilly’s New RNAi Partner Aims for Two Doses a Year

Eli Lilly and SanegeneBio team up to create long-acting RNAi drugs for obesity and diabetes

10 Nov 2025

Eli Lilly’s latest wager in the race to reshape metabolic medicine comes with a Chinese accent. The American drugmaker has struck a deal worth up to $1.2 billion with SanegeneBio, a Shanghai-based biotechnology firm, to develop RNA interference (RNAi) treatments for obesity and type 2 diabetes, diseases that already sustain some of the world’s biggest pharmaceutical revenues.

Under the agreement, SanegeneBio will lead early discovery work while Lilly takes charge of clinical trials and, if successful, global sales. Financial details were not disclosed, though the scale of the arrangement suggests that Lilly’s appetite for next-generation metabolic therapies is only growing.

SanegeneBio’s LEAD platform aims to deliver RNAi drugs capable of silencing harmful genes for several months. If proven, that could replace the frequent injections patients now rely on with just two doses a year. “This partnership combines RNAi innovation with the muscle of a global pharmaceutical leader,” says Dr Karen Liu, a biotech analyst. “It reflects a shift toward therapies that last longer and treat the root of disease, not just the symptoms.”

The deal comes as demand for GLP-1 drugs such as Ozempic and Mounjaro has surged, turning the obesity and diabetes markets into a corporate feeding frenzy. Yet competition is intensifying: rival firms are racing to match Lilly’s success with Mounjaro. Longer-acting RNA therapies could help the firm distinguish itself in an increasingly crowded field.

Plenty could still go wrong. RNAi therapies remain difficult to deliver safely in humans, and regulatory approval for new mechanisms of action is never swift. But if the partnership succeeds, it could redefine how chronic metabolic disorders are managed and what patients expect from treatment.

For now, Lilly’s move signals confidence that the next phase of the weight-loss revolution will rely less on willpower or weekly injections, and more on the quiet work of silencing genes.